Ascendis Pharma A/S
NASDAQ:ASND
Ascendis Pharma A/S
Operating Income
Ascendis Pharma A/S
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Ascendis Pharma A/S
NASDAQ:ASND
|
Operating Income
-€447.7m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
N/A
|
|
Genmab A/S
CSE:GMAB
|
Operating Income
kr5.3B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
31%
|
CAGR 10-Years
54%
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Operating Income
-kr561.2m
|
CAGR 3-Years
2%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-12%
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Operating Income
kr2.1B
|
CAGR 3-Years
75%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
51%
|
Bioporto A/S
CSE:BIOPOR
|
Operating Income
-kr60.2m
|
CAGR 3-Years
2%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-12%
|
|
Saniona AB
STO:SANION
|
Operating Income
-kr79.3m
|
CAGR 3-Years
21%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
See Also
What is Ascendis Pharma A/S's Operating Income?
Operating Income
-447.7m
EUR
Based on the financial report for Dec 31, 2023, Ascendis Pharma A/S's Operating Income amounts to -447.7m EUR.
What is Ascendis Pharma A/S's Operating Income growth rate?
Operating Income CAGR 5Y
-24%
Over the last year, the Operating Income growth was 20%. The average annual Operating Income growth rates for Ascendis Pharma A/S have been -11% over the past three years , -24% over the past five years .